Tempus AI Q2 revenue $382.5M (+22% YoY); raises FY2026 guidance to $1.595-1.605B

Tempus AI, Inc.

Revenue $382.5M, up 22% YoY; GAAP net income $5.6M vs loss $42.8M in Q2 2025.
Adjusted EBITDA $8.0M vs -$5.6M; FY2026 revenue guidance raised to $1.595-1.605B.
Signed ~$200M in new Data and Applications licenses; MRD volume 9,000 tests.
Agreed to acquire Personalis for $16.25/share (~$1.5B enterprise value).
FDA approved xT Tumor Only CDx assay; first lab with both tumor-only and tumor-normal CDx.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.